Details for New Drug Application (NDA): 214324
✉ Email this page to a colleague
The generic ingredient in TYVASO DPI is treprostinil. There are nineteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the treprostinil profile page.
Summary for 214324
Tradename: | TYVASO DPI |
Applicant: | United Therap |
Ingredient: | treprostinil |
Patents: | 7 |
Pharmacology for NDA: 214324
Physiological Effect | Vasodilation |
Suppliers and Packaging for NDA: 214324
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
TYVASO DPI | treprostinil | POWDER;INHALATION | 214324 | NDA | United Therapeutics Corporation | 66302-610 | 66302-610-02 | 1 KIT in 1 PACKAGE (66302-610-02) * 4 INHALANT in 1 BLISTER PACK * 4 INHALANT in 1 BLISTER PACK * 4 INHALANT in 1 BLISTER PACK |
TYVASO DPI | treprostinil | POWDER;INHALATION | 214324 | NDA | United Therapeutics Corporation | 66302-616 | 66302-616-03 | 4 BLISTER PACK in 1 KIT (66302-616-03) / 7 BLISTER PACK in 1 BLISTER PACK / 4 INHALANT in 1 BLISTER PACK |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | POWDER;INHALATION | Strength | 0.016MG/INH | ||||
Approval Date: | May 23, 2022 | TE: | RLD: | Yes | |||||
Regulatory Exclusivity Expiration: | May 23, 2025 | ||||||||
Regulatory Exclusivity Use: | NEW PRODUCT | ||||||||
Patent: | 10,130,685 | Patent Expiration: | Aug 23, 2025 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | 10,421,729 | Patent Expiration: | Apr 1, 2035 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription